Edesa Biotech Stock (NASDAQ:EDSA)
Previous Close
$1.99
52W Range
$1.55 - $5.99
50D Avg
$1.95
200D Avg
$3.72
Market Cap
$6.34M
Avg Vol (3M)
$38.12K
Beta
0.84
Div Yield
-
EDSA Company Profile
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
EDSA Performance
Peer Comparison
| Ticker | Company |
|---|---|
| LGVN | Longeveron Inc. |
| PCSA | Processa Pharmaceuticals, Inc. |
| SNTI | Senti Biosciences, Inc. |
| ADTX | Aditxt, Inc. |
| NTRB | Nutriband Inc. |
| VRAX | Virax Biolabs Group Limited |
| LIXT | Lixte Biotechnology Holdings, Inc. |
| SABS | SAB Biotherapeutics, Inc. |
| REVB | Revelation Biosciences, Inc. |
| QNRX | Quoin Pharmaceuticals, Ltd. |
| KTTA | Pasithea Therapeutics Corp. |
| INDP | Indaptus Therapeutics, Inc. |
| RNXT | RenovoRx, Inc. |
| CING | Cingulate Inc. |
| THRD | Third Harmonic Bio, Inc. |
| PSTV | Plus Therapeutics, Inc. |
| PALI | Palisade Bio, Inc. |